SCHEMBL12434263

SCHEMBL12434263

COc1ccccc1CCNC(=O)c1ccccc1-c1ccccc1CNC(=O)Nc1ccc(C(F)(F)F)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 2/20 0.55
CNR1 P21554 1/20 0.54
KMT2A Q03164 5/20 0.50
MEN1 O00255 3/20 0.50
ALDH1A1 P00352 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
MCHR1 Q99705 1/20 0.48
HTT P42858 2/20 0.48
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
NAMPT P43490 1/20 0.47
MAPT P10636 3/20 0.47
TP53 P04637 1/20 0.47
CDK4 P11802 1/20 0.46
CCND1 P24385 1/20 0.46
HPGD P15428 1/20 0.46
GOT1 P17174 1/20 0.46
ROCK2 O75116 1/20 0.45
RXFP1 Q9HBX9 1/20 0.44
MTNR1A P48039 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13789528 0.82 KCNA5 (0.52) KCNA5CNR1NPC1RAB9AMAPT
SCHEMBL12434260 0.82 CNR1 (0.54) KCNA5CNR1KMT2AMEN1HPGD
SCHEMBL12434271 0.82 KCNA5 (0.58) KCNA5CNR1KMT2ANPC1RAB9A
SCHEMBL13789465 0.81 KCNA5 (0.52) KCNA5CNR1KMT2AMEN1NAMPT
SCHEMBL12434281 0.80 MEN1 (0.56) KCNA5CNR1KMT2AMEN1ALDH1A1
SCHEMBL12434229 0.78 KCNA5 (0.69) KCNA5KMT2AALDH1A1SMN1; SMN2MAPT
SCHEMBL3062492 0.78 MTNR1A (0.60) KMT2AMEN1HTTNAMPTMAPT
SCHEMBL12434249 0.77 SORT1 (0.54) KCNA5KMT2ASMN1; SMN2HTTNPC1
SCHEMBL12434256 0.75 KCNA5 (0.62) KCNA5CNR1ALDH1A1SMN1; SMN2NPC1
SCHEMBL12434243 0.74 KCNA5 (0.61) KCNA5CNR1KMT2AMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7982045-B2 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2011-07-19 US disclosed
US-7982045-B2 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2011-07-19 US disclosed
US-20090192096-A1 2'-Substituted 1,1'-Biphenyl-2-Carboxamides, Processes For Their Preparation, Their Use As Medicaments, And Pharmaceutical Preparations Comprising Them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-07-30 US disclosed
US-20090192096-A1 2'-Substituted 1,1'-Biphenyl-2-Carboxamides, Processes For Their Preparation, Their Use As Medicaments, And Pharmaceutical Preparations Comprising Them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-07-30 US disclosed
US-7514582-B2 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-04-07 US disclosed
US-7514582-B2 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192096-A1 2'-Substituted 1,1'-Biphenyl-2-Carboxamides, Processes For Their Preparation, Their Use As Medicaments, And Pharmaceutical Preparations Comprising Them MLLT3, RYR2, CACNA1E KCNA5 90/4885CNR1 61/4885KMT2A 1473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.